Comanagers May and McEldowney replaced by team.
How accounts are protected and how you can access your records.
A resurgence doesn't take away the sting of 2001's first quarter.
Drugs figure prominently but aren't a problem for a change.
Though doing better, American Century Income & Growth still lags.
Fund still lolls after rough first quarter.
After a relatively poor 2000, the fund loses more than most in 2001.
Fund shows upside and downside strength.
This fund's recent moderation hasn't been enough in 2001.
New manager cuts back biotech, favors stocks with steadier earnings.
Vanguard Health Care displays resilience after a strong 2000.
This fund scored big in 2000 and has been competitive since.
Fund is down, but it's competitive with its biotech-focused peers.
Aggressive biotech investing has been a painful discipline lately for Franklin Biotech Discovery.
Janus Global Life Sciences has been falling behind its specialty-health competition for nearly 12 months.
Fund hopes to lessen tax burden as a compliment to high returns.
Comanager Tom Wald promoted in wake of John Schroer's departure.
Here's how how to turn last year's losers into your next year's winners.
October saw an increase in new money invested in mutual funds, with stock funds nearly doubling September flows.
Brian Posner joined Warburg Pincus because he believed he could play a significant role--now he's looking for the next place he can have an impact.
As the U.S. stock market paces through 1999 at a less feverish pace than in recent years, mutual-fund investor enthusiasm seems to have cooled, too.